Core Viewpoint - The report outlines the equity change of Qingdao Haier Biomedical Co., Ltd. (referred to as "Haier Biomedical") due to an increase in shareholding by Qingdao Jiushi Investment Management Co., Ltd. through its fund Jiushi Preferred No. 1, which acquired 15,897,909 shares, representing 5% of the total share capital of the company, from August 14, 2024, to October 14, 2025 [8][15]. Group 1: Information Disclosure Obligations - The information disclosure obligations are based on the Securities Law of the People's Republic of China and related regulations, ensuring that the report covers all changes in shareholding [1]. - The information disclosure obligor confirms that the report does not contain any false records, misleading statements, or significant omissions, and assumes legal responsibility for its authenticity and completeness [2]. Group 2: Purpose and Future Plans of Equity Change - The purpose of the equity change is driven by a long-term positive outlook on the life sciences industry and recognition of Haier Biomedical's performance in governance, industry position, business capabilities, operational results, and risk management [5]. - There are currently no explicit plans or agreements for increasing or decreasing shareholding in the next 12 months, and any future changes will be disclosed in accordance with relevant laws and regulations [7]. Group 3: Details of Equity Change - From August 14, 2024, to October 14, 2025, Jiushi Preferred No. 1 increased its shareholding in Haier Biomedical by 15,897,909 shares, funded by its own capital [8]. - Following this equity change, Jiushi Preferred No. 1 has become a shareholder holding more than 5% of the company's shares [9]. Group 4: Impact on Company Control - The equity change will not alter the controlling shareholder or actual controller of Haier Biomedical [16].

Core Viewpoint - The report outlines a significant equity change involving Wuhan New Generation Technology Co., Ltd., which has been ordered by the court to transfer 16,234,261 shares of Hubei Huaron Holdings Co., Ltd. to settle debts with Jilin Jiutai Rural Commercial Bank Co., Ltd. The total value of the shares is approximately 84.47 million yuan [4][8]. Group 1: Company Information - The information disclosure obligor is Wuhan New Generation Technology Co., Ltd., located in Wuhan, Hubei Province [1]. - The company held 16,234,261 shares of Hubei Huaron Holdings, representing 8.30% of the total share capital before the equity change [7][12]. Group 2: Purpose and Plan of Equity Change - The equity change is a result of a court ruling from the Jilin Province Changchun Intermediate People's Court, which mandated the transfer of shares to satisfy a debt [4][8]. - There are no plans for Wuhan New Generation Technology Co., Ltd. to increase its shareholding in Hubei Huaron Holdings within the next twelve months [5]. Group 3: Legal and Compliance - The report confirms that the information disclosure obligor has obtained necessary authorizations and that the report complies with relevant laws and regulations [2]. - The report asserts that there are no false records or misleading statements, and the obligor takes legal responsibility for the accuracy and completeness of the information [2][17].

登录新浪财经APP 搜索【信披】查看更多考评等级 上市公司名称：浙江东望时代科技股份有限公司 上市地点：上海证券交易所 股票简称：东望时代 股票代码：600052 信息披露义务人：浙江野风堂信息咨询有限公司 住所/通讯地址：浙江省东阳市歌山镇北江工业区 股份变动性质：间接转让（增加） 签署日期：2025年9月 信息披露义务人声明 一、信息披露义务人根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》（以下简称"《证券法》"）、《上市公司收购管理办法》（以下简称"《收购管理办法》"）、 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》（以下简称"《准则15 号》"）及相关法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反信息披露义务人章程或内 部规则中的任何条款，或与之相冲突。 三、依据《证券法》和《收购管理办法》的规定，本报告书已全面披露信息披露义务人在浙江东望时代 科技股份有限公司中拥有权益的股份变动情况。截至本报告书签署之日，除本报告书披露的信息外，上 述信息披露义务人没有通过任何其他方式增加或减少其在浙江东望时 ...

Core Viewpoint - The company Zhejiang Jingu Co., Ltd. announced a non-trading transfer of shares by its controlling shareholders to repay stock pledge financing debts, which will not affect the company's control structure or operations [3][4][18]. Group 1: Share Transfer Details - Controlling shareholders Sun Jinguo and Sun Liqiong signed a share pledge disposal agreement with Hangzhou Stable Development Fund on September 25, 2025, transferring a total of 31,850,191 shares at a price of 10.659 CNY per share [3][4][13]. - Sun Jinguo transferred 11,282,636 shares (1.13% of total shares), while Sun Liqiong transferred 20,567,555 shares (2.07% of total shares) [3][4]. - After the transfer, Sun Jinguo will hold 39,824,825 shares (4.00% of total shares), and Sun Liqiong will no longer hold any shares [3][4]. Group 2: Financial Implications - The total amount for the share transfer is aimed at repaying a debt of approximately 527.17 million CNY owed by a third party, with the transferred shares valued at 339.49 million CNY [9][12][13]. - The transfer is part of a strategy to reduce debt and mitigate pledge risks for the controlling shareholders [18]. Group 3: Regulatory Compliance - The transaction complies with relevant laws and regulations, including the Company Law and Securities Law, and does not violate any existing commitments [18]. - The acquiring fund is prohibited from reducing its holdings within six months following the transfer [4][18]. Group 4: Company Governance - The share transfer will not lead to a change in the controlling shareholders or the governance structure of the company [4][18]. - The company will continue to monitor the share transfer process and ensure compliance with legal requirements [19].

南财智讯9月24日电，品茗科技公告，通智清研（北京）科技产业发展合伙企业（有限合伙）通过协议 转让方式受让莫绪军等股东持有的1255.22万股股份，占上市公司总股本的15.92%，转让价格为39.504 元/股，总金额约为4.96亿元。本次权益变动后，通智清研成为持有上市公司15.92%股份的股东，未涉 及上市公司控制权变化。通智清研表示，本次权益变动基于对上市公司长期投资价值的认可。 ...

Group 1 - The company Shanghai Mankou Pharmaceutical Co., Ltd. plans to issue shares to specific investors, with the proposal approved by the board and supervisory committee on September 22, 2025 [1][3][27] - The issuance is subject to approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][27] - The company will hold its second extraordinary general meeting of shareholders on October 9, 2025, to discuss the share issuance and other related matters [4][5][8] Group 2 - The share issuance involves the subscription of 163,901,373 ordinary shares at a price of RMB 6.30 per share, totaling approximately RMB 1,032.58 million [30][32][33] - The shares will be locked for 36 months post-issuance, preventing transfer during this period [35][39] - The controlling shareholder after the issuance will be Nanjing Haiqing Pharmaceutical Co., Ltd., with a shareholding of 20% in Mankou Pharmaceutical [28][30] Group 3 - The company has committed to maintaining its independence in operations, assets, and finances post-transaction, ensuring no conflicts of interest arise [51][52][54] - There are no plans for significant changes to the company's main business or major asset disposals in the next 12 months [41][43] - The company has established measures to avoid any potential competition with its controlling shareholder's business [55]

Core Viewpoint - The report outlines the equity change of Nanjing Haiqing Pharmaceutical Co., Ltd. (海鲸药业) regarding its acquisition of shares in Shanghai Mengke Pharmaceutical Co., Ltd. (盟科药业), aiming to gain control over the latter through a directed share issuance. Group 1: Equity Change Details - Nanjing Haiqing Pharmaceutical plans to acquire 163,901,373 shares of Shanghai Mengke at a price of RMB 6.30 per share, totaling approximately RMB 1,032.58 million [20][21] - This acquisition will result in Nanjing Haiqing holding 20% of Shanghai Mengke's total shares post-issuance, making it the controlling shareholder [17][18] - The equity change does not trigger any mandatory tender offer obligations [3] Group 2: Purpose and Decision-Making Process - The purpose of the equity change is to gain control over Shanghai Mengke, leveraging its product pipeline and operational capabilities for sustainable development [11] - The decision-making process included approvals from the board of directors and supervisory board of both companies on September 22, 2025 [14] Group 3: Financial and Operational Commitments - Nanjing Haiqing commits to ensuring the independence of Shanghai Mengke in terms of assets, personnel, finance, and operations [40][41] - The company has no plans to change the main business operations of Shanghai Mengke in the next 12 months [32] Group 4: Compliance and Regulatory Aspects - The acquisition is compliant with relevant laws and regulations, with necessary approvals from the board and shareholders required before execution [25][15] - Nanjing Haiqing has confirmed that the funds for the acquisition will be sourced from its own capital or legally raised funds [29]

Core Viewpoint - Draka Comteq B.V. has reduced its stake in Changfei Optical Fiber and Cable Co., Ltd. from 5.00% to 0.00% through the sale of 37,595,257 H-shares on September 19, 2025, via a block trade on the Hong Kong Stock Exchange [8][10]. Group 1: Company Information - Changfei Optical Fiber and Cable Co., Ltd. is listed on the Shanghai Stock Exchange (A-shares) and the Hong Kong Stock Exchange (H-shares) with stock codes 601869 (A-shares) and 06869 (H-shares) [1]. - The registered address of Draka Comteq B.V. is Schieweg 9, 2627AN Delft [2]. Group 2: Shareholding Changes - The shareholding change was made for financial management and business development needs [6]. - Draka Comteq B.V. has no plans to increase or decrease its stake in the company within the next 12 months [7]. - The total share capital of Changfei Optical Fiber and Cable Co., Ltd. is calculated to be 751,905,108 shares after excluding 6,000,000 treasury shares [4]. Group 3: Transaction Details - The sale of 37,595,257 H-shares represents 5.00% of the total share capital of the company [8]. - Prior to this transaction, Draka Comteq B.V. had sold additional H-shares in the preceding months, including 28,246,771 shares on April 17, 2025, and 32,968,500 shares on June 5, 2025 [10][11].

Core Points - Shanghai Huidet Technology Co., Ltd. announced a change in the equity holdings of its controlling shareholder, Shanghai Huidet Enterprise Group Co., Ltd., and its concerted parties, which triggered a 1% threshold change [1] - Before the change, the total holding ratio was 69.08%, which decreased to 68.78% after the completion of the 2024 restricted stock incentive plan, resulting in an increase in total shares from 141,132,667 to 141,754,417 [1] - The change in holdings was due to passive dilution of shares held by the controlling shareholder and its concerted parties, and it did not trigger a mandatory tender offer, violate commitments, or lead to changes in the controlling shareholder or actual controller [1]

Core Viewpoint - The report details the equity changes of JinkoSolar Holding Co., Ltd. (晶科能源) due to a share transfer involving several entities, resulting in a reduction of their combined shareholding from 68.93% to 64.93%, which touches a 5% integer threshold [19][22]. Group 1: Equity Change Details - The equity change involves a total reduction of 400,208,099 shares, representing approximately 4.00% of the company's total share capital [11][22]. - Prior to the equity change, the combined shareholding of the disclosing parties was 6,896,552,000 shares, accounting for 68.97% of the total shares [10][27]. - Following the equity change, the total shares held by the disclosing parties decreased to 6,496,343,901 shares, which is about 64.93% of the total share capital [10][11]. Group 2: Purpose and Method of Equity Change - The purpose of the equity change is to meet the financial needs of the disclosing parties through an inquiry transfer method, rather than through centralized bidding or block trading [9][22]. - The inquiry transfer price was set at 4.90 yuan per share, with the transfer executed on September 18, 2025 [20][30]. - The disclosing parties, including JinkoSolar Investment Co., Ltd. and several limited partnerships, are considered concerted actors, maintaining control over the company [7][23]. Group 3: Compliance and Disclosure - The disclosing parties have ensured that the report and related documents are truthful, accurate, and complete, taking legal responsibility for any misrepresentation [4][16]. - The report complies with relevant laws and regulations, including the Securities Law of the People's Republic of China and the rules governing the disclosure of equity changes [1][4].